Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing its lead drug candidate Lucid-MS for multiple sclerosis while simultaneously pursuing commercial growth with its unbuzzd product, according to Executive Co-Chairman and Co-Founder Anthony Durkacz during a recent episode of the BioMedWire Podcast. The company’s strategy combines clinical-stage pharmaceutical development with commercial opportunities across neurodegenerative, metabolic and alcohol-misuse conditions.
Durkacz highlighted Lucid-MS’s goal of addressing mobility damage associated with MS and noted that the company has filed an investigational new drug application for a Phase 2 clinical trial, which could represent the candidate’s first administration to human MS patients. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The potential impact of this program is significant for the estimated 2.8 million people worldwide living with MS, as current therapies primarily target inflammation rather than repair of myelin damage.
Beyond its clinical pipeline, Quantum BioPharma has commercialized unbuzzd, a product designed to accelerate alcohol metabolism. The company spun out the over-the-counter version to Unbuzzd Wellness Inc. (UWI), led by industry veterans, while retaining a 19.84% ownership stake as of March 31, 2026, and royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma also retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses. This dual revenue stream—royalties from unbuzzd and potential future sales of Lucid-MS—provides a diversified financial model that could buffer the company during the lengthy drug development process.
The news matters because it illustrates a growing trend among biotech firms to generate near-term revenue through commercial products while pursuing long-term drug development. For investors, this approach may reduce risk compared to companies solely reliant on clinical trials. For patients, Lucid-MS represents a potential breakthrough in treating the underlying cause of MS disability, not just symptoms. Anthony Durkacz’s discussion on the podcast provides insight into the company’s strategy and milestones, including the upcoming Phase 2 trial. More details are available in the full article at https://ibn.fm/IWnPQ and the company’s newsroom at https://ibn.fm/QNTM.
Forward-looking statements in this article involve risks and uncertainties, as detailed in the company’s filings with the SEC. Quantum BioPharma undertakes no duty to update this information unless required by law.
